IL-6 Stabilization in Serum Using Alkyl Trimethylammonium Halogenide
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for stabilizing interleukin-6 (IL-6) in serum are insufficient, leading to challenges in production, storage, and quality control due to its short stability and high cost associated with frequent additions during process control.
Innovation Solution
A composition comprising IL-6 and a specific concentration range (0.15% to 0.4%) of C10-C18-alkyl trimethylammonium halogenide compounds, which enhances the stability of IL-6 in serum, allowing for improved recovery and extended storage without additional IL-6 additions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If conventional stabilization methods (sugars, salts, polyalcohols) are used for IL-6, then protein structural stability is improved, but IL-6 stability in serum is insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the chemical composition parameters of the stabilization system. Instead of using conventional excipients (sugars, salts, polyalcohols), the invention introduces compounds with specific chemical characteristics (ammonium salts with particular molecular structures) that fundamentally change the stabilization mechanism. This parameter change in chemical composition enables effective IL-6 stabilization in serum where conventional methods fail.
2Ease of operation
If IL-6 is stored in liquid phase without effective stabilization, then ease of operation is improved, but shelf life is reduced due to short stability
Solution Approach 1:
The patent introduces ammonium salt compounds as intermediary substances that mediate between IL-6 and the serum environment. These intermediaries prevent direct destabilizing interactions between IL-6 and serum components, enabling long-term stability in the convenient liquid phase without requiring freezing or frequent replenishment.
3Reliability
If frequent IL-6 additions are made during process control to compensate for degradation, then IL-6 activity is maintained, but manufacturing cost increases
Solution Approach 1:
The patent applies preliminary action by incorporating stabilization compounds into the formulation before storage and use. This pre-stabilization prevents IL-6 degradation during storage and processing, eliminating the need for frequent monitoring and replenishment operations. The preliminary protective action reduces both operational complexity and material costs.
Data Source
AI summary
Disclosed is a composition including IL-6, an isoform or a fragment thereof, a compound of the formula C10-C18-alkyl trimethylammonium halogenide (I), wherein the compound is saturated or unsaturated and/or substituted or unsubstituted, or a salt thereof, wherein the concentration of the compound in the composition is about 0.15 to about 0.4%, and a serum. Also disclosed is a kit including a composition or a lyophilisate and instructions for use. A further embodiment of the present invention is method of stabilizing IL-6, an isoform or a fragment thereof, including the steps of mixing IL-6, an isoform or a fragment thereof, a compound of the formula C10-C18-alkyl trimethylammonium halogenide (I), wherein the compound is saturated or unsaturated and/or substituted or unsubstituted, or a salt thereof, wherein the concentration of the compound in the composition is about 0.15 to about 0.4%, and a serum.